Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Descartes-08 in cSLE, AAV, JMG, and JDM
NCT07089121Phase 2Recruiting
- Sponsor
- Cartesian Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of Descartes-08 in systemic lupus erythematosus (SLE), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), myasthenia gravis (MG), juvenile dermatomyositis (JDM), sponsored by Cartesian Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
Descartes-08
03
Conditions
systemic lupus erythematosus (SLE)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)myasthenia gravis (MG)juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on NCT07089121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089121.